A carregar...
Dual Fulvestrant‐Trametinib Therapy in Recurrent Low‐Grade Serous Ovarian Cancer
Low‐grade serous ovarian carcinoma (LGSOC) is known to exhibit chemoresistance. Effective treatment options for recurrent disease are few and often limited to hormone antagonism. Combination of endocrine therapies with MEK‐inhibitors displays synergism in preclinical ovarian cancer models, however....
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7356701/ https://ncbi.nlm.nih.gov/pubmed/32369640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0101 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|